Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for AVITA Medical (RCEL) over the last 4 years, with Q4 2025 value amounting to $323000.0.

  • AVITA Medical's Current Deferred Revenue fell 952.38% to $323000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $323000.0, marking a year-over-year decrease of 952.38%. This contributed to the annual value of $323000.0 for FY2025, which is 952.38% down from last year.
  • AVITA Medical's Current Deferred Revenue amounted to $323000.0 in Q4 2025, which was down 952.38% from $331000.0 recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Current Deferred Revenue ranged from a high of $698000.0 in Q4 2022 and a low of $205000.0 during Q2 2024
  • For the 4-year period, AVITA Medical's Current Deferred Revenue averaged around $414000.0, with its median value being $365000.0 (2024).
  • In the last 5 years, AVITA Medical's Current Deferred Revenue tumbled by 6319.57% in 2024 and then soared by 6585.37% in 2025.
  • Quarter analysis of 4 years shows AVITA Medical's Current Deferred Revenue stood at $698000.0 in 2022, then tumbled by 44.13% to $390000.0 in 2023, then fell by 8.46% to $357000.0 in 2024, then decreased by 9.52% to $323000.0 in 2025.
  • Its Current Deferred Revenue stands at $323000.0 for Q4 2025, versus $331000.0 for Q3 2025 and $340000.0 for Q2 2025.